Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance

Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance

Abstract Background Lung cancer is the leading cause of cancer deaths worldwide in both men and women, and non-small cell lung cancer (NSCLC) accounts for the majority (~ 85%) of lung cancers. This post-marketing surveillance (PMS) study aimed to evaluate the safety of Pemetrexed (Alvopem®, NanoAlva...

Full description

Bibliographic Details
Main Authors: Sharareh Seifi, Babak Salimi, Zahra Esfahani Monfared, Cyrus Sabahi, Hamidreza Kafi, Adnan Khosravi
Format: Article
Language:English
Published: Taylor & Francis Group 2023-01-01
Series:Journal of Pharmaceutical Policy and Practice
Subjects:
Non-small cell lung cancer
Observational study
Pemetrexed
Post-marketing surveillance
Safety
Online Access:https://doi.org/10.1186/s40545-023-00524-5

Internet

https://doi.org/10.1186/s40545-023-00524-5

Similar Items